OmniAb (OABI) Scheduled to Post Earnings on Tuesday

OmniAb (NASDAQ:OABI - Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Persons interested in registering for the company's earnings conference call can do so using this link.

OmniAb (NASDAQ:OABI - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05. The business had revenue of $7.61 million for the quarter, compared to analysts' expectations of $6.52 million. OmniAb had a negative net margin of 287.29% and a negative return on equity of 20.21%. During the same quarter last year, the firm earned ($0.15) EPS. On average, analysts expect OmniAb to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OmniAb Stock Performance

OABI traded up $0.17 during midday trading on Tuesday, reaching $4.50. 436,493 shares of the company were exchanged, compared to its average volume of 501,787. The company has a market cap of $531.72 million, a price-to-earnings ratio of -6.98 and a beta of -0.12. OmniAb has a one year low of $3.56 and a one year high of $6.72. The company's fifty day moving average price is $4.15 and its 200 day moving average price is $4.28.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on OABI. Royal Bank of Canada reiterated an "outperform" rating and set a $7.00 price target on shares of OmniAb in a report on Friday, August 16th. Benchmark reiterated a "buy" rating and issued a $8.00 target price on shares of OmniAb in a report on Monday, August 19th. Finally, HC Wainwright restated a "buy" rating and set a $11.00 price target on shares of OmniAb in a report on Monday, August 12th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.